Changyoun Kim1,2, Dong-Hwan Ho1,2, Ji-Eun Suk1,2, Sungyong You3, Sarah Michael4, Junghee Kang5, Sung Joong Lee5, Eliezer Masliah4, Daehee Hwang3, He-Jin Lee2,6 & Seung-Jae Lee1,2
1 Department of Biomedical Science and Technology, Konkuk University, Seoul 143-701, Republic of Korea. 2 SMART-IABS, Konkuk University, Seoul 143-701, Korea. 3 School of Interdisciplinary Bioscience and Bioengineering, and Department of Chemical Engineering, POSTECH, Pohang 790-784, Korea. 4 Department of Neurosciences and Pathology, School of Medicine, University of California San Diego, La Jolla, California 92093-0624, USA. 5 Department of Neuroscience, School of Dentistry and Dental Research Institute, and Interdisciplinary Program in Genetic Engineering, Seoul National University, Seoul 110-749, Korea. 6 Department of Anatomy, School of Medicine, Konkuk University, Seoul 143-701, Korea.
Correspondence to : Seung-Jae Lee
Abstract
Abnormal aggregation of α-synuclein and sustained microglial activation are important contributors to the pathogenic processes of Parkinson’s disease. However, the relationship between disease-associated protein aggregation and microglia-mediated neuroinflammation remains unknown. Here, using a combination of in silico, in vitro and in vivo approaches, we show that extracellular α-synuclein released from neuronal cells is an endogenous agonist for Toll-like receptor 2 (TLR2), which activates inflammatory responses in microglia. The TLR2 ligand activity of α-synuclein is conformation-sensitive; only specific types of oligomer can interact with and activate TLR2. This paracrine interaction between neuron-released oligomeric α-synuclein and TLR2 in microglia suggests that both of these proteins are novel therapeutic targets for modification of neuroinflammation in Parkinson’s disease and related neurological diseases.